BUSINESS
Everstone Group picks stake in Chennai-based medical devices maker CPC Diagnostics
With this strategic investment, Everlife plans to support CPC’s manufacturing and distribution capabilities within India and South-East Asia, to become the leading IVD distributor in the region.
BUSINESS
L&T poised to meet FY19 order inflow guidance on pre-election boost
L&T needs around Rs 42,000 crore in the fourth quarter to meet the FY19 guidance.
BUSINESS
Bharat Biotech's Zika, Chikungunya vaccines to enter Phase II trials; focus now on private label market
So far there are no vaccines in the world against Zika and Chikungunya.
BUSINESS
This week in pharma: MMR vaccine and autism link refuted; Facebook clamps down hard on misinformation
The anti-vaccine movement never fully abated, but subsided largely due to evidence of vaccines as effective tools in improving public health.
BUSINESS
Opto Circuits to pare debt by raising funds from PE investors and asset sale
After a three-year slide in business, Opto Circuits was able to stymie losses with a profit of Rs 35 crore and revenues of Rs 225 core in FY18.
BUSINESS
Amid tough times, private hospitals face shortage of CEOs
The rapid expansion of private healthcare facilities over last one decade, has not just created shortage of specialist doctors but qualified senior administrators to manage them.
BUSINESS
Commissioner Scott Gottlieb exits USFDA, Indian firms curious on agency's future course
Actions by the US drug regulator impacts Indian manufacturers, who generate significant revenue by selling copycat drugs at a fraction of the cost in the world's largest market for medicines
BUSINESS
Novartis leads the way in using data and AI to find new drugs, improve R&D productivity
One of the initiative Data 42, called as ‘moonshot’ project within Novartis, is trying to harness the power of data analytics, machine learning and AI to possibly find leads for new drugs, new patient approaches and identifying safety features, by wringing new insights out of old clinical trials data.
BUSINESS
Lupin's Nilesh Gupta says new launches will help turn the corner in coming quarters
Lupin is hoping to turn the corner in the US, led by key approvals of generic versions of Renexa and Synthroid in place and a possible launch of Albuterol MDI in second half of FY20.
BUSINESS
Weekly wrap: Indian pharma loses its powerful voice with demise of DG Shah
Shah who was well networked, understood the IPR, trade, regulatory and drug pricing policies in depth, was a natural leader to lead the Indian pharmaceutical industry.
BUSINESS
Indian drug makers show improvement in USFDA inspection outcomes
According to USFDA data, out of 174 inspections in 2018 only 4 percent inspections are classified as OAI, attracting agency’s regulatory and administrative action such as withholding new approvals, warning letter and import alert, in contrast to 15 percent in 2017.
BUSINESS
China's Fosun to expand Gland Pharma operations in India
Frank Yao, Co-Chairman, Fosun Pharma who was in India, told Moneycontrol that the integration process of Gland Pharma with Fosun is over, and Fosun has plans to expand manufacturing footprint and add more products to the pipeline.
INDIA
Govt caps trade margins of 42 cancer drugs
Currently, 57 anti-cancer drugs are under price control as scheduled formulations.
BUSINESS
CDSCO to consider waiving off clinical trials for orphan drugs
While currently there is no definition on orphan drugs in India, medicines that are used in treatment rare diseases, with less than five lakh patients, typically fall under this category.
BUSINESS
Manipal Hospitals-Medanta deal will take more time to close, says top executive
Manipal, led by Ranjan Pai, was in race to buy Fortis Healthcare last year, but Malaysia’s IHH Healthcare outbid their rivals to buy the troubled healthcare provider.
BUSINESS
Pharma weekly wrap: USFDA lifts warning on Dr Reddy's Duvvada unit, relief after Bachupally observations
Duvvada resolution is expected to give a huge fillip to the company, as around 20% of its future ANDA (abbreviated new drug applications) filings were made from this facility.
BUSINESS
Aster DM to build budget hospitals in Gulf to meet demand from insured workers
In an exclusive interview over phone from Dubai, Moopen told Moneycontrol that insurance coverage to workers increased volumes but also put pressure on margins, as insurance companies now started pushing for steep discounts on package rates.
BUSINESS
Bharat Biotech acquires Chiron Behring Vaccines from GSK for undisclosed amount
The acquisition allows Hyderabad-headquartered Bharat Biotech to become world's largest manufacturer of rabies vaccines.
BUSINESS
USFDA Form 483 points to repeat observations at Dr Reddy's Bachupally plant
Out of 11, four are repetitive observations made by the agency in its inspection in 2017, while one observation goes even back to 2015 inspection.
BUSINESS
Laurus Labs invests over $100 million on formulation biz
In an exclusive interview, Laurus Labs CEO Satyanarayana Chava said the drug maker has invested around Rs 750-800 crore on developing products and building factories.
BUSINESS
Sun Pharma up against challenges as it builds speciality biz in US
"We committed close to a $1 billion on specialty business, we have to justify that investment and produce returns," Dilip Shanghvi said in the company's earnings call on February 12.
BUSINESS
Delhi HC sets aside govt ban on Lupin's diabetes drugs
Gluconorm-PG is a triple combination of diabetes drugs Glimepiride, Metformin, Pioglitazone, with sales of around Rs 50 crore.
BUSINESS
Sun Pharma responds to SEBI queries on super-stockist Aditya Medisales, 2004 FCCB issue
MD Dilip Shanghvi assures investors that at no point of time Sun Pharma's minority shareholders were disadvantaged in transactions with Aditya Medisales
BUSINESS
Indian pharma lobby seeks removal of India from US patent violator list
IPA has drawn the attention of USTR to the rapid progress made by India on a number of fronts, which were cited by USTR while placing India on the Priority Watch List in 2018
